A glycoconjugate (dLPS-CBSA) from hydrazine-detoxified lipopolysaccharide (LPS) of Vibrio cholerae O139 and BSA was used for immunization of BALB/c mice. The immunogenicity (concentration of induced IgG antibodies) of the conjugate was determined by enzyme-linked immunosorbent assay. The highest level of LPS-specific IgGs was found in sera collected 2 weeks after the third immunization. Both IgM and IgG antibodies present in the anti-V. cholerae O139-specific sera showed long-lasting vibriocidal activity. The glycoconjugate also stimulated production of IL-4, IL-6, IFNc, TNFa and IL-10. Immunization with the conjugate induced significant production of both Th1 and Th2 cytokine sets, indicating balanced Th1/Th2 immune response polarization. The quantitative analysis of total and LPS-specific IgM and IgG antibodies production by B lymphocytes (from both the spleen and the bone marrow) was performed by ELISPOT assay. From the analysis of antibodies produced directly by B lymphocytes in the bone marrow (of dLPS-CBSA immunized mice), we were able to identify the IgM-IgG switch in the antibodies produced.
Introduction
The O139 serogroup of Vibrio cholerae has emerged in the 1990s as only the second of over 200 known serogroups of V. cholerae with epidemic potential to cause disease in human population. The O139 pathogen appears to have arisen from V. cholerae O1 El Tor by acquisition of new lipopolysaccharide (LPS) locus. The latter contains genes that allow synthesis of capsule that is not present in O1. This 'new' serogroup has the potential of being responsible for the 8th pandemic of cholera. Therefore, development of a vaccine against the disease caused by V. cholerae 139 would be of great importance.
Initially, several oral cholera vaccines, based on either inactivated or live attenuated bacteria, have been developed to provide protection against the disease caused by the newly emerged serogroup [1] [2] [3] [4] . Later, PS-based glycoconjugate preparations were investigated [5] [6] [7] [8] . The advantages of glycoconjugate vaccines over pure glycans in inducing immune responses are well documented [9] . Conjugate vaccines are superior to non-conjugated antigens for immunizing young children against diseases caused by encapsulated bacteria. Such vaccines have been successful in reducing the severity of outcome following infection with Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis [10] .
The LPS is the major constituent of the outer membrane of Gram-negative bacteria [11] . It is also the dominant protective antigen of V. cholerae and represents the antigen of choice for cholera vaccine design [12] . Bacterial LPS is a T cell-independent (TI) antigen. The B cell immune response to TI antigens is without immunological memory, characteristic of production of only IgM and without IgMIgG class switching [13] . In contrast, proteins require T cell participation to induce antibody synthesis and, thus, are called T cell-dependent (TD) antigens. It is generally accepted that for induction of effective long-term immunological protection, the involvement of T-lymphocytes is needed. Therefore, for use in vaccines, it is highly desirable to transform TI polysaccharide antigens into TD antigens. This can be accomplished by conjugation of T-independent polysaccharide antigen to a protein carrier. Conjugate vaccines, in which the polysaccharide is attached to an immunogenic carrier protein, are able to induce a T celldependent immune response, are immunogenic even in infants and have been shown to prime for immune memory [14] . Immunization with a glycoconjugate provides T cell help for B cells, which now produce high-affinity IgG antibodies to the LPS component. Thus, glycoconjugates induce polysaccharide-specific IgM to IgG switching, memory B cell development and long-lived T cell memory.
We have previously revealed a novel structure of glycoconjugate derived from V. cholerae O139 hydrazine-treated LPS [8] and have demonstrated the immunological efficacy of V. cholerae LPS preparations [15] [16] [17] . The aim of this study was to determine the humoral, long-lasting cellmediated immune response to novel dLPS-CBSA construct. The data obtained should be useful for developing immunomodulation strategies within research towards anti-V. cholerae O139 conjugate vaccines.
Materials and methods
Vaccine antigen. The synthesis and characterization of V. cholerae O139 conjugate (dLPS-CBSA) have been previously described [8] . Briefly, bovine serum albumin (BSA) was treated with succinic acid anhydride in mild alkali solution to label all reactive amino groups of BSA with carboxyl groups. Carbohydrate-protein conjugate was prepared by reaction of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride-activated carboxylated BSA (CBSA) with base-detoxified LPS (dLPS). According to MALDI TOF mass spectrometry, the dLPS-CBSA conjugate contained, on average, 2-3 dLPS residues per one CBSA molecule.
Immunization of mice and blood sampling. Mice (BALB/c, female, 6 weeks old, Research Institute of Animal Production, Velaz, Prague, Czech Republic) were used as host animals. Mice groups (each containing 10 mice) were injected subcutaneously with dLPS alone (2.5 lg/dose) or dLPS-CBSA conjugate in 2-week intervals (without any adjuvant).
Immunization schedule: day 0 -the first immunization day 14 -the first booster day 28 -the second booster Blood samples were collected on day 0 -pre-immune sera, day 14 -after the first immunization, day 28 -after the first booster, day 42 -after the second booster, day 56 -2 weeks after the second booster and on day 77 -5 weeks after the second booster vaccination.
Ethics statement. Animal experiments were conducted in accordance with revised Helsinki declaration and followed the criteria for the welfare of experimental animals and complied with the ethical guidelines issued by the Research Base of Slovak Medical University, Institute of Preventive and Clinical Medicine (Bratislava, Slovakia), under the approval no. Ro 2939/09-221 of the State Veterinary and Food Administration of the Slovak Republic.
Isolation of lymphocytes from tissues. Two or five weeks after the third immunization, mice were anesthetized and bled from plexus orbitalis before collection of tissues. Spleens were removed and flushed with complete tissue culture medium using a 21G needle (CTCM; RPMI-1640, 10% fetal bovine serum, penicillin-streptomycin (100 U and 100 lg/ml, respectively)) to obtain single-cell suspensions. Bone marrow was flushed with CTCM medium from the medullary cavities of femurs using a 20G needle. Filters (CellTrics, 50 lm, Partec GmbH, Germany) were used for marrow single-cell isolation from bone marrow tissue. Splenocytes and bone marrow cells were pooled per group, pelleted (380 g/10 min), washed with CTCM, dyed with T€ urk's solution and counted.
ELISA, antibody titration. Mice anti-V. cholerae O139 LPS IgG antibody titres were determined by ELISA method. Immulon 4 HBX microplates (Dynex, Chantilly, VA, USA) were coated with LPS (10 lg/ml) in carbonate buffer (pH 9.6) overnight at 4°C. Next, the plate washing with TBS was repeated three times. Blocking procedure (2 h, room temperature) was accomplished by diluted 1:20 (v/v) Milk Diluent/Blocking Solution Concentrate (KPL, Milford, USA) in distilled water. Titrations of sera were performed stepwise with serial dilution, starting with 1:10 and ending with 1:12,800. Subsequently, the plates were incubated 2 h at room temperature and washed three times with TBS. Igs were detected using goat anti-mouse IgG-AP antibody, dilution 1:3000 in PBS (Beckman Coulter, Fullerton, CA, USA). As a substrate, BluePhos Microwell Phosphatase Substrate System (KPL) was used. Reaction was stopped by addition of 2.5% Na 2 EDTA Á 2H 2 O.
Antibody titres in serum for LPS were expressed as the reciprocal of the highest positive dilution. Final titres are expressed as the mean AE SD of triplicate determinations.
Vibriocidal assay. The long-lasting serum vibriocidal effect on days 42 and 77, mediated by IgM/IgG antibodies, was carried out against V. cholerae O139 by an in vitro microdilution assay, modified by Quadri [18] and described by Korcov a et al. [17] . Final values of optical densities were corrected with respect to the individual samples (blanks measured at 0 h, 590 nm) and converted to a percentage of reduction in vibrios colonies (Fig. 2) .
Lasting vibriocidal activity mediated by IgG was detected by inactivation of IgM by mixing equal volumes of sera with 0.2 M 2-mercaptoethanol (2-ME) and incubation at 4°C overnight [19] .
Quantitative detection of cytokines. Cytokines in sera were measured in duplicates using specific ELISA kits for IL-4, IL-6, IFNc, TNFa and IL-10 (BioLegend, London, UK). The conversion of measured absorbance values (MRX photometer for microtiter plates, 630 nm) to pg/ml was performed from the calibration curve generated using standards included in each kit.
Memory B cell assay. Mice anti-LPS V.cholerae O139-specific IgG and IgM antibody-secreting B cells were determined by ELISPOT method [20] . In preparation for the ELISPOT, 96-well MultiScreen â HTS TM IP Sterile Plates (Millipore, Tullagreen, Ireland) were coated with dLPS (10 mg/ml). To detect all IgG and IgM antibodysecreting cells (ASC), separate plates were coated with 15 lg/ml goat anti-mouse IgG and goat anti-mouse IgM (Bethyl Laboratories, Montgomery, USA). Plates were washed three times with PBS, pH 7.2 and blocked by 10% fetal bovine serum in PBS at 37°C for 30 mins. The cells isolated from the spleen or bone marrow were washed with CTCM, applied onto the ELISPOT plates (2x10 6 cells per ml) and incubated at 37°C for 30 min. Plates were then washed three times with PBS, pH 7.2 and incubated for 2 h with goat anti-mouse IgG (H+L chain) and goat anti-mouse IgM alkaline phosphatase-conjugated antibodies (Beckman Coulter, Maryfort, Ireland). The plates were again washed three times with PBS, pH 7.2 and developed using SigmaFAST TM BCIPâ /NBT as a substrate (SigmaAldrich, Schnelldorf, Germany). Quantitative evaluation of spots and enumeration of LPS-specific antibody-secreting B cells were performed via KS ELISPOT 4.10 using Imager A.1 Microscope running AxioVision (Zeiss, Oberkochen, Germany).
Statistical analysis. Data were evaluated for statistical significance of differences by one-way ANOVA followed by Bonferroni's multiple comparison tests. All data were expressed as mean AE SD. Levels of statistically significant differences are as follows: ***P < 0.001, **0.001 < P < 0.01, *0.01 < P < 0.05.
Results

Antibody response induced by dLPS-CBSA conjugate
In this work, we set out to assess whether dLPS-CBSA conjugate induced significant immunological protection. We measured specific anti-mouse IgG titres against LPS by ELISA assay using serum collected from dLPS-CBSAvaccinated mice. Dilution ≤ 1:12,800 of dLPS-CBSA conjugate serum is the highest dilution in linear curve range. We compared levels of IgG antibodies with the cutoff control value in titre 1:6400 was 0.52 (0.48 + 2 SD). Antibody assay against dLPS from V. cholerae O139 showed IgG absorbance levels in titre 1:6400 and already in 1:3200, that is 5 weeks after the last dose of vaccination in day 77, to be 29 higher compared to the IgG levels in the same titres in sera collected from mice only 2 weeks after the last dose on day 56 (Fig. 1A, B) .
Long-lasting vibriocidal antibody response
Vibriocidal assay is an important method for the prediction of the protective effect of antigen-induced IgM and IgG antibodies. Long-lasting vibriocidal activity of tested undiluted mice sera on day 42 and 77 after the second booster injection is presented in Fig. 2 .
Long-lasting vibriocidal activity against V. cholerae O139 was mediated by both antibody isotypes, that is IgM and IgG. The highest vibriocidal effect, compared to control sera (mice injected by physiological saline only), was observed in the sera of the mice immunized by dLPS-CBSA conjugate. Serum vibriocidal activity was mediated here by both IgM and IgG antibodies. Long-lasting serum vibriocidal activity effected by IgG after dLPS immunization was not detectable.
Conjugate dLPS-CBSA stimulates IL-4, IL-6, IFNc, TNFa and IL-10 production in serum
To establish the involvement of T-immune cells and specifically Th1/Th2 polarization of immune responses which induced immunization by dLPS-CBSA, we evaluated relevant cytokine levels in sera 2 and 5 weeks after second booster injection of dLPS-CBSA conjugate, and compared them with levels in sera of control mice (Fig. 3) . The second booster injection of dLPS-CBSA induced markedly higher levels of Th2-associated cytokines IL-4 (8.99 higher 2 weeks after second dLPS-CBSA conjugate boost and 5.89 higher 5 weeks after second dLPS-CBSA conjugate boost, Fig. 3A ) and IL-6 (6.29 higher 2 weeks after second dLPS-CBSA conjugate boost and 5.39 higher 5 weeks after second dLPS-CBSA conjugate boost, Fig. 3B ). The second booster injection of dLPS-CBSA conjugate also induced a significant increase in levels of Th1-associated cytokine IFNc (4.99 higher 2 weeks after second dLPS-CBSA conjugate boost and 1.99 higher 5 weeks after second dLPS-CBSA conjugate boost, Fig. 3C ). The second booster injection of dLPS-CBSA conjugate induced very low increase in TNFa and IL-10 levels (Fig. 3D, E) .
Measurement of LPS-specific IgG and IgM antibody-secreting B cells (ASC) in the spleen and bone marrow
Measurement of LPS-specific IgG and IgM antibody-secreting B cells (ASC) in the spleen
Lipopolysaccharide-specific IgM and IgG antibody-secreting B cells in the spleen were determined by ELISPOT assays and were performed on days 0, 14, 28, 42 and 77. When both LPS-specific IgG and IgM ASC in mice vaccinated with dLPS-CBSA conjugate grew, the levels of IgM and IgG ASC of mice vaccinated with only dLPS had a decreasing tendency (Fig. 4A, B) . Throughout the assay, IgG ASC in mice vaccinated with dLPS-CBSA conjugate reached higher levels, compared to IgM ASC levels.
During the immunization, the significant number of LPS-specific IgG ASC in mice vaccinated with CBSA differed from those vaccinated with dLPS (as positive controls, Fig. 4A ). On day 14 after priming, the significant number of LPS-specific ASC for dLPS-CBSA and mice vaccinated with only dLPS was revealed (94 versus 51, in a representative experiment of three replicates). On day 28 (after the first booster), the number of LPS-specific ASC in mice vaccinated with dLPS-CBSA was 7.89 higher than in those vaccinated with dLPS only (212 versus 27). Likewise, on day 2, the number of LPS-specific ASC in mice vaccinated with dLPS-CBSA was 7.99 higher than in mice vaccinated with only dLPS (238 versus 30). Although on day 77 (5 weeks after the second booster) the number of LPS-specific IgG ASC in mice vaccinated with only dLPS increased, it was still 5.39 lower than in mice vaccinated with dLPS-CBSA (247 versus 46).
The number of LPS-specific IgG-secreting ACS in mice vaccinated with dLPS-CBSA steadily increased with time, and it peaked on day 77 and was 3.79 higher than in mice vaccinated with dLPS (240 versus 65, in a representative experiment of three replicates).
Measurement of LPS-specific IgG and IgM antibody-secreting B cells (ASC) in the bone marrow
The number of LPS-specific IgM and IgG ASC in the bone marrow was determined by ELISPOT assays on days 0, 14, 28, 42 and 77 (Fig. 4C, D) . We observed an increase in LPS-specific IgG and IgM in mice vaccinated with dLPS-CBSA during the immunization schedule. The number of LPS-specific IgG ASC in mice vaccinated with dLPS-CBSA steadily increased with time, and it peaked on day 77 and was 6.89 higher than in those vaccinated with dLPS only (247 versus 36, in a representative experiment of three replicates).
Lipopolysaccharide-specific IgM ASC in the bone marrow appeared already after the first immunization of mice (day 14) with dLPS-CBSA conjugate. On day 28, after the second immunization (the first booster), the amount of LPS-specific ASC in mice vaccinated with dLPS-CBSA was 29 higher than in mice vaccinated with dLPS only (142 versus 59). Two weeks after the second booster (day 42), the number of specific IgM ASC in mice vaccinated with dLPS-CBSA slightly decreased, peaked on day 77 (5 weeks after the second booster) and was 2.89 Figure 2 Long-lasting vibriocidal activity of undiluted sera after the second booster -last injection (day 42) and 5 weeks after (day 77) represented by IgM + IgG together and by IgG antibodies only, expressed as killed bacterial cells in %. The experimental data are expressed as geometric means AE SEM. Levels of significance: ***, 0.000 < P < 0.001; **, 0.001 < P < 0.01, *, 0.01 < P < 0.05. ................................................................................................................................................................ higher than in mice vaccinated with dLPS only (240 versus 83).
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It is obvious that in the case of immunization by dLPS-CBSA conjugate, the LPS-specific IgG memory B cells in the spleen and the bone marrow are present for a long time after immunization.
Discussion
Lipopolysaccharide-containing conjugates are promising tools within the development of a cholera vaccine. The aim of this study was to analyse the underlying immune responses associated with dLPS-CBSA-induced protection Figure 3 Cytokine detection in the serum from mice vaccinated with dLPS-CBSA, dLPS only and physiological saline 2 and 5 weeks after the second booster injection. (A) IL-4 production, (B) IL-6 production, (C) IFNc production, (D) TNFa production and (E) IL-10 production. Each bar represents the mean AE SD. Comparisons of groups vaccinated with dLPS-CBSA and dLPS only with those vaccinated with the saline control sera. Levels of significance: ***, 0.000 < P < 0.001; **, 0.001 < P < 0.01, *, 0.01 < P < 0.05. Differences were considered significant where 0.01 < P < 0.05. of the host. Therefore, in this work, the immunogenicity of dLPS-CBSA conjugate was examined.
The advantages of glycoconjugate vaccines over pure polysaccharides in inducing immune responses are well documented [9] . Chemical conjugation of a T cellindependent dLPS to a carrier protein BSA mediates the induction of T cell-dependent immune response to the carbohydrate epitope. Efficient T cell-dependent responses are manifested by the LPS-specific IgM-IgG switching, memory B cell (MBC) development and long-lasting T cell memory.
Vibriocidal activity is an important predictor of protective effect of antigen-induced antiserum. Serum anti-LPS antibodies are the main component exerting the vibriocidal activity [15] . The long-lasting vibriocidal effect of serum after immunization by dLPS-CBSA conjugate was mediated by IgM as well as by IgG antibodies. The mechanism of protection against cholera is not yet known, but the antibody vibriocidal response that largely targets LPSs is the best known indirect correlation of protection [21, 22] . The antibodies are bactericidal in the presence of a complement, and most of their activity against LPS is of the IgM isotype [22, 23] . Although higher titres have been associated with protection against V. cholerae O1 infection and disease, there is no threshold at which the protection is complete [24] . Serum anti-LPS antibodies are the main component exerting the vibriocidal activity. A plausible explanation for the phenomenon could be that the serum antibodies as well as complement proteins exude onto the surface of the intestine. The relatively small inoculum of V. cholerae (10 3 ) was susceptible to complement-mediated lysis induced in the intestine. Evidently, the novel dLPS-CBSA conjugate induced effective anti-IgG and IgM antibody levels with sufficient vibriocidal properties (Fig. 2) .
Immunization with the conjugate induced Th1 and Th2 immune responses, as indicated by the elevation of relevant cytokine levels (Fig. 3) . These data provide some insights into the immunomodulatory properties of glycoconjugate at hand [25] . ............................................................................................................................................................... Memory B cells have potential to rapidly differentiate into novel antibody-secreting plasma cells, with even more adapted antibodies upon re-exposure to antigen or infection [26] . Understanding the mechanism by which vaccines generate and sustain these B cell subpopulations is essential to explaining and predicting the long-term efficacy of vaccines which mediate protection through functional antibodies [27] . MBCs develop following natural infection and immunization, and could be the entity by which the long-term immunity to cholera is mediated [28] . These cells are responsible for anamnestic antibody responses following re-exposure to antigen, which stimulates the differentiation of MBC into antibody-secreting cells (ASC). MBC responses to LPS antigen may be a useful surrogate marker of the protection and a tool for the development and assessment of improved cholera vaccines [29] .
We studied cell suspensions derived from the spleen and the bone marrow, presumed sites for short-lived plasma cells and MBCs on the one hand and long-lived plasma cells on the other hand [30] [31] [32] . A number of studies have implied that secretion of IgM is a prerequisite for optimal induction and formation of germinal centre (GC) reactions and IgG production [33] .
Memory B cells are found in the circulation after natural infection. Accordingly, vaccination plays a critical role in mediating long-term protective immunity by facilitating rapid anamnestic antibody responses upon re-exposure to antigen [28] .
A study with patients infected with V. cholerae O1 or O139 showed that adults mounted higher LPS-induced IgG levels at convalescence, compared to children [34] . Induction of IgG is a very important due to its ability to penetrate the intestinal epithelium and initiate complement-mediated lysis of the bacterial inoculum [5] . Antigen-specific IgM is the first antibody isotype to rise in the serum after exposure to antigen and plays an important role in subsequent affinity maturation and isotype switching, giving way to other antibody isotype such as high-affinity IgG [33] . In adults with V.cholerae O1 infection, IgM responses against LPS elevated by day 7, after onset of the illness, and remain persistently elevated above baseline for at least 30 days, the last period examined [35] . This finding is not unexpected, as the vibriocidal antibody is mostly composed of IgM directed against LPS [22] . Such investigations are needed given the importance of IgM antibody in humoral immunity against T cell-independent antigens, such as LPS [36] , and its role in long-term immunity involving MBCs [35] .
Immunological memory is a hallmark of the immune system and is necessary for the successful immunization. Assessment of the immunological memory induced by priming of the immune system by vaccination should be an important factor in evaluating candidate vaccines [15, 17, 37, 38] .
